What tirzepatide costs long-term once you reach a maintenance dose — monthly and annual — and why flat-rate pricing makes the long-term math predictable.
Maintenance is the ongoing phase once you reach your target dose (often 10–15 mg). Because therapy is typically long-term, the maintenance-dose price matters more than the starting price.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Compounded, flat | $186/mo* (~$2,232/yr) | Not FDA-approved |
| Zepbound® LillyDirect (10–15 mg, within window) | Brand | $449/mo (~$5,388/yr) | FDA-approved |
| Zepbound® standard self-pay (10–15 mg) | Brand | $699–$1,049/mo | FDA-approved |
| Brand retail | Brand | ~$1,086/mo (~$13,032/yr) | FDA-approved |
Annual figures are illustrative (monthly × 12). Flat-rate compounded keeps the maintenance price equal to the starting price. Verified July 2026.
Most people remain on a maintenance dose for an extended period, and weight regain is common after stopping — so the maintenance price compounds over time. Flat-rate pricing makes the long-term math predictable: the same $186/month whether you're at 10 mg or 15 mg. For the per-mg value at maintenance doses, see cost per mg; for stopping considerations, see safety & eligibility. Compounded tirzepatide is not FDA-approved.
Flat-rate compounded maintenance is $186/month (~$2,232/year); Zepbound LillyDirect maintenance is $449/month within the refill window (~$5,388/year). Compounded is not FDA-approved. See NexLife pricing
Many people remain on a maintenance dose long-term, and weight regain is common after stopping. Your clinician guides duration; results vary by patient.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.